Oral JAK inhibitors unlikely to be totally shut out in eczema by black box warning
Dermatologists point to several uptake openings for JAK inhibitors in moderate-to-severe eczema despite highly publicized side effect concerns.
By
Dermatologists point to several uptake openings for JAK inhibitors in moderate-to-severe eczema despite highly publicized side effect concerns.
ByTheravance's ampreloxetine and Novartis in rare disease are among recent events reviewed by GlobalData’s Investigative News team.
BySanofi’s pemphigus asset, Artios solid tumor trial among recent events reviewed by GlobalData’s Investigative News team.
ByGlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
ByGilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said.
ByThe firms may struggle to convince regulators that their HIF PHIs don't share roxadustat’s safety concerns in CKD.
ByTrial updates and data releases across the pharma space moved the needle when it came to several drugs’ approval and…
ByThe investigator-led trial has so far recruited 45 out of 183 patients despite enrolment opening in July last year.
ByThank you for subscribing to Clinical Trials Arena